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literature demonstrate that the outcome can also be influenced by the insulin
regimen used by the hospital. Objective of this study is the Budget Impact Analysis
(BIA) of the hospital use of aspart insulin with respect to other rapid insulin alter-
natives available on the market. METHODS: All the hospitalizations with evidence
of hyperglycaemia in one year in Italy were considered. Four alternatives were
evaluated: 1) aspart insulin; 2) lispro insulin; 3) glulisine insulin; 4) human insulin.
Administration of insulin regimen (basal rapid), length of hospital stay and inci-
dence of hypoglycaemic events were simulated. The rates of hypoglycaemic events
with rapid insulin alternatives, and the prolongation of hospital stay caused by
such an event were derived from international literature. Only differential costs
among alternatives were accounted for, i.e. purchase and administration of rapid
insulin and management of hypoglycaemic events. Epidemiologic and healthcare
resource consumption data derived from Italian published sources. Current prices
and tariffs were applied in the perspective of the hospital. RESULTS: A total of 7.7
million hospitalizations of adult patients in one year were considered, of which
23.6% (1.8 million) with evidence of hyperglycaemia. Total costs with the aspart
insulin resulted: €7.8 million for insulin, €7.4 million for administration and €507.0
million for hypoglycaemic events management (total: €522.2 million). Total costs
with the other rapid insulin alternatives were higher (range: 4% to 37.2%).
CONCLUSIONS: Aspart insulin has a listed purchasing cost in Italy equal or higher
than alternatives, but the BIA indicates that its adoption can yield savings for the
hospital, being the hypoglycaemic events management the main cost driver.
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THERAPIES VIA DISPOSABLE PENS AMONG PATIENTS WITH TYPE 2 DIABETES
IN US EMPLOYER-SPONSORED HEALTH PLANS
Du J1, Wei W2, Xie L1, Pan C3, Baser O1
1STATinMED Research, Ann Arbor, MI, USA, 2sanofi-aventis U.S., Inc, Bridgewater, NJ, USA,
3Pro Unlimited, Boca Raton, FL, USA
OBJECTIVES: Among patients with type-2 diabetes mellitus (T2DM) previously
treated with only OADs, to evaluate real-world differences in clinical and economic
outcomes following initiating basal analog insulin therapy via disposable pen with
either glargine (GLA-P) or detemir (DET-P). METHODS: The MarketScan databases
(2006–2010) were used to identify patients with T2DM aged 18–79 years and receiv-
ing 1 OAD, but no insulin before initiation of GLA-P or DET-P. Patients had con-
tinuous health plan enrollment for 6 months prior to (baseline) and 1 year after
GLA-P or DET-P initiation (follow-up). Propensity score matching 1:1 was applied to
match the two patient cohorts using baseline demographic and clinical factors.
Study outcomes included treatment persistence and adherence, hypoglycemia-
related medical events, and healthcare utilization and costs during the follow-up.
RESULTS: The 2 matched cohorts (n5771 each, mean age 54, female 49%) were
well balanced for baseline characteristics (all P0.1). During follow-up, patients
initiating GLA-P were more likely to be persistent (42.9 vs. 38.4%, P0.001) and
adherent (adjusted medication possession ratio 0.70 vs. 0.67, P0.001) with treat-
ment versus those initiating DET-P. The average daily study drug consumption
dose was 33U in both cohorts. Fewer GLA-P than DET-P users returned to OAD-only
(18.6 vs. 20.5%, P0.011). Hypoglycemia-related medical events were similar (0.7 vs.
1.0%, P0.093), while the mean number of hypoglycemia-related emergency room
(ER) or hospital events per patient was lower for GLA-P (0.006 vs. 0.012, P0.010).
The diabetes-related pharmacy costs were similar for GLA-P and DET-P ($2,465 vs.
$2513, P0.155), as were the total health care costs ($16,058 vs. $16,209, P0.69).
CONCLUSIONS: Real-world T2DM patients initiating insulin therapy via disposable
pen with GLA-P were more likely to persist and adhere with treatment compared
with patients initiating with DET-P. GLA-P users had fewer ER-/hospital-related
hypoglycemia events, while costs were similar for both.
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OBJECTIVES: The aim of this analysis was to estimate the long-term incremental
clinical and cost outcomes associated with exenatide once weekly (EQW) versus
sitagliptin therapy in type 2 diabetes patients in the UK. Data from DURATION-2; a
phase 3, multinational, randomised, double-blind clinical trial in 491 patients with
type 2 diabetes previously treated with metformin were used. After 26 weeks,
patients receiving EQW (n160) had a significantly greater LS mean HbA1c reduc-
tion (-1.6% versus -0.9%, respectively) and weight reduction (-2.3 kg versus -0.8 kg,
respectively) than patients who received sitagliptin (n166). METHODS: A previ-
ously published and validated diabetes model (IMS CORE Diabetes Model) was used
to make 50 year projections of clinical and cost outcomes based on DURATION-2
baseline patient characteristics and study results. Costs were derived from pub-
lished sources and expressed in 2010 UK Pounds. A discount rate of 3.5 % was
applied to both costs and outcomes. Various sensitivity analyses were performed.
RESULTS: EQW treatment was projected to improve quality-adjusted life expec-
tancy by 0.22 quality-adjusted life years (QALYs) (95% confidence interval 0.12 to
0.32) versus sitagliptin. Total direct medical costs associated with EQW were pro-
jected to be higher over patient lifetimes than with sitagliptin (difference of £1405,
95% confidence interval £444 to £1982), due to higher drug acquisition costs, which
were partially offset by the lower incidence of diabetes-related complications dur-
ing treatment with EQW, and hence cost of treating. The projected incremental
cost effectiveness ratio (ICER) was £6418 per QALY gained. Results of the sensitivity
analysis showed that the ICER was influenced by a reduction in time horizon,
decrease in EQW benefits on HbA1c and increased time on EQW. CONCLUSIONS:
Projected from the DURATION-2 trial, EQW can be considered cost-effective versus
sitagliptin in the UK setting from the NHS perspective. The results were robust to
sensitivity analyses.
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OBJECTIVES: The aim of this analysis was to estimate the cost-effectiveness of
exenatide once weekly (EQW) versus exenatide BID therapy, two formulations of
the same glucagon-like peptide-1 receptor agonist molecule, in type 2 diabetes
patients in the UK. Pooled data from DURATION-1 and DURATION-5, phase 3, ran-
domised, open label clinical trials in 295 and 252 patients respectively, were used.
EQW was associated with greater LS mean HbA1c reduction (-1.7% versus -1.2%,
respectively, p0.001) and weight reduction (-2.9 kg versus -2.4 kg, respectively,
p0.126). METHODS: A previously published and validated diabetes model (IMS
CORE Diabetes Model) was used to make 50 year projections of clinical and cost
outcomes based on pooled DURATION-1 and 5 baseline patient characteristics (age
55.3 years, duration of diabetes 7 years, HbA1c 8.36%) and study results. Costs were
derived from published sources and expressed in 2010 UK Pounds. A discount rate
of 3.5 % was applied to both costs and outcomes. Various sensitivity analyses were
performed. RESULTS: EQW treatment was projected to improve quality-adjusted
life expectancy by 0.18 quality-adjusted life years (QALYs) (95% confidence interval
0.10 to 0.25) and life expectancy by 0.16 years (95% confidence interval 0.07 to 0.26)
versus exenatide BID. EQW was associated with delayed onset of any diabetes-
related complication versus exenatide BID by almost 6 months on average. Due to
the lower incidence of diabetes-related complications during treatment with EQW,
and hence reduction in their treatment costs, EQW was associated with direct
medical cost savings (difference of -£305, 95% confidence interval -£715 to £35).
EQW was therefore projected to be dominant versus exenatide. This result was
robust to all sensitivity analysis. CONCLUSIONS: Based on DURATION-1 and 5,
EQW was projected to be less costly and more effective than exenatide BID over a
patients’ lifetime in the UK setting.
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OBJECTIVES: The World Health Organization has recognized diabetes and other
selected chronic health conditions are at an epidemic level all of which can be
impacted by weight. The purpose of this project was to evaluate the role of diabetes
and Body Mass Index (BMI) on total medical expenses. METHODS: The Medical
Expenditure Panel Survey (MEPS) is publically available database providing nation-
ally representative estimates of health care use, expenditures, sources of payment,
and health insurance coverage for the US population. Analysis of the survey data
utilized design-based methods that utilized the complex survey stratification and
weighting. Regression was utilized to determine the effect of diabetes and BMI
class on total medical expenses in 2008, with inclusion of age, gender, race/ethnic-
ity, and insurance status as additional covariates. Models with and without two-
way interactions were performed. Summary statistics are presented as mean 
standard error. RESULTS: All adults (18 years; n22,128) were included, and av-
erage 2008 medical expenses were estimated at $4493  105. All variables in the
model were significant (p0.001), and adjusting for these factors, patients with
diabetes had an average medical expense of $4,512 410 higher than those without
diabetes. Across both cohorts, the morbid obese (BMI 40) had significantly higher
covariate adjusted medical expenses than normal (18.5 BMI25; $1340  414;
p0.001) and overweight (25 BMI30; $1517  420; p0.001) individuals,
whereas differences with obese (30 BMI40; $784  439; p0.08) and under-
weight (BMI18.5; -$88  754; p0.91) were not significant. CONCLUSIONS: Both
diabetes and high BMI are independently associated with significantly higher med-
ical expenses, and appear to be generally an additive effect. Increase in BMI was
associated with significantly higher medical costs even without diabetes. Morbidly
obese patients with diabetes had annual expenses averaging $12,004.
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OBJECTIVES: To model and evaluate consequences of enhanced treatment of type
2 diabetes mellitus on cost, life expectancy and development of complications in
the Bulgarian health care system. METHODS: The extensively published and vali-
dated CORE Diabetes Model was used to perform lifetime simulations for the rep-
resentative diabetic patient in Bulgaria diagnosed at 55 years. The analysis com-
pared two alternative treatment scenarios with current standards of care. In the
first alternative scenario the model examined the human and economic costs of
10% reduction in the risk factors for developing diabetes related complications. In
the second scenario consequences of treating to targets set in American Diabetes
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Association (ADA) guidelines were simulated. Cost of treatment and complications
were based on officially published sources for medicines prices (www.mh.govern-
ment.bg), for hospital charges (www.nhif.bg) and verified by expert opinion survey
(1 BGN 0.51 EUR). Future costs were discounted with 5%. RESULTS: Treatment to
targets postpones minor complications by up to 4 years, delays major complica-
tions by 3 to 4 years and extends life expectancy from diagnosis by 3 years com-
pared with the baseline scenario. Total discounted cost savings over remaining life
expectancy from the diagnosis were from 2483 BGN to 2908 BGN per person.
CONCLUSIONS: Enhanced treatment leads to avoidance or delay of the complica-
tions of diabetes. This significantly reduces the impact diabetes can have on pa-
tients’ quality of life, life expectancy and cost of diabetes treatment in Bulgarian
health care system settings.
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BACKGROUND: Under the data of Russian Federal State Registry 2010 there are
around 3 million patients in diabetes. Also data of epidemiology assessment in the
frame of national project Health demonstrates that estimated number of patients
consists of 5-7% from total population that is 4 times higher. Death rate of cardio-
vascular complications is 1.5 thousand people per year. Every second patient gets
invalidity. So total expenditures for complications treatment tens times more than
costs on medical products and control devices. OBJECTIVES: 1) Provide local costs
of the disease, and 2) Assess benefits of new technology treatment versus tradi-
tional therapy.METHODS: Retrospective analysis of case studies of patients in D2T
from 4 regions of Russia. Average age - 61 years, duration of D2T - 7.5 years, body
mass index - more than 32 kg/m3, Hb1Ac - 8.1%. Isolation of two groups of patients:
1 - treated with adding of vildagliptin (n264); 2 - treated by traditional OAD with
sulfonylurea (n600). Comparative analysis Cost of Illness of two groups, and
correlation between antidiabetic medical products and risk of fatal complications.
RESULTS: Average cost of antidiabetic medical treatment of group 1 versus 2 is
more than 2 times expensive, 16,600 rub versus 7,000 rub per patient rep year.
Exchange rate is $1  30 rub. But total costs for the treatment of patients group 2
versus 1 is 30% higher (26,000 rub and 18,000 rub per patient per year accordingly).
The main reason - more number of vital important cardiovascular events and
exacerbations of hypertension and heart disease in group 2. Part of direct medical
costs for the treatment without antidiabetic products is 7% and 73% from total
costs for groups 1 and 2 accordingly. CONCLUSIONS: Usage of new antidiabetic
products - vildagliptin is a way to control of diabetes, development of cardiovas-
cular complications and total budget for the disease.
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OBJECTIVES: The prevalence of diabetes continues to grow, and it is estimated that
in Croatia we have 315.900 adults with diabetes (9.2% adult population), although in
many patients the disease has not yet been diagnosed. Majority of patients - 92,8%
suffers from diabetes mellitus type 2. The objectives of this study are to quantify
the economic burden of illness caused by increased health resource use and to
provide detailed breakdown of the costs attributed to diabetes. METHODS: Preva-
lence-based cost-of-illness methodology was used to estimate the direct costs
(hospital care, drugs, physician care, institutional care, additional costs) and indi-
rect costs (sickness leave) associated with micro and macro vascular complica-
tions, diabetes monitoring and drugs analyzed by types of diabetes complication
and health resource categories. RESULTS: Total cost of diabetes mellitus type 2 in
Croatia sums to 11,49% of national insurer‘s budget, i.e. 351,7 mil EUR in 2009.
Direct medical costs include 50,2 mil EUR to directly treat and monitor diabetes,
and 301,5 mil EUR to treat diabetes-related chronic complications. Diabetes medi-
cations make 8,75% of total illness cost. The largest components of medical expen-
ditures are hospital inpatient care (36,75%) and prescriptions for treating compli-
cations (28,49%). Hypertension and cardiopathy incur largest amount of
expenditures related to diabetes complications (76,2 mil EUR), followed by acute
myocardial infarction (68,6 mil EUR) and peripheral vascular disease (52 mil EUR).
Indirect costs equal 4,6 mil EUR. CONCLUSIONS: An average expenditure per per-
son with diagnosed diabetes type 2 in Croatia is 1.956 EUR yearly. These cost data
provide additional rationale for better disease monitoring and complication pre-
vention.
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OBJECTIVES: Diabetes mellitus (DM) is a major health problem with severe com-
plications and a significant impact on quality of life. It constitutes an enormous
burden of disease due to high prevalence, severe co-morbidities and high costs for
society. This study is the first comprehensive study on direct and indirect cost of
DM (type 1 and type 2) and its complications in Poland. METHODS: In order to
estimate the direct medical costs of DM and its complications, including the costs
of medical consultation, hospitalization, rehabilitation, drugs and medical equip-
ment data for the years 2004-2009 of the National Health Fund were used. Indirect
costs like costs of pensions for incapacity for work, the costs of rehabilitation and
loss of productivity due to diabetes and its complications were obtained from the
Department of Social Security for the years 2004-2009. RESULTS: Direct medical
costs of DM in Poland increased in the analysed period. The significant share of
these costs constitutes the costs of drugs (25.7% increase 2005 vs. 2007). Direct costs
of DM treatment, without costs of drugs, increased in the analysed period at similar
rate (type 1 – 22,7%, type 2 – 22,1%). The highest costs are associated with treatment
of diabetes complications. The total cost of treatment of DM showed in the anal-
ysed period an upward trend. The indirect costs are mainly determined by loss of
productivity, cost of pensions for incapacity for work and cost of rehabilitation. The
number of diabetic patients receiving pensions for incapacity for work is declining,
but this trend is being seen in the whole disability pensions system in Poland.
CONCLUSIONS: From year to year DM causes a growing economic burden on the
health care and to the Polish society in terms of health care and productivity loses.
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OBJECTIVES: To determine the financial cost of diabetes management to Cocoa
clinics for 2009. METHODS: A descriptive cross-sectional study of diabetes man-
agement at the four Cocoa clinics in Ghana from May to July 2010 was conducted.
The prevalence-based ‘Cost-of-illness’ approach from the institutional perspective
was employed. A pre-tested data extraction form was used to review the medical
records of 304 diabetes patients randomly selected. RESULTS: The mean age was
55.4 years. The annual financial cost of managing one diabetes patient was esti-
mated to be GH¢ 541.35 (US$ 373.34). Service cost constituted 22% whiles direct
medical cost was 78%. Drug cost was 71% of the financial cost. The cost of hospi-
talization per patient-day at Cocoa clinic was estimated at GHø 32.78 (US$ 22.61).
The total financial cost of Diabetes management was estimated at GH¢ 420,087.67
(US$ 289,715.63). This accounted for 8% of the total expenditure for the Clinics in
year 2009. The study showed that facility type, type of diabetes and presence of
complications is associated with the cost of Diabetes management to Cocoa clinics.
CONCLUSIONS: The cost of managing Diabetes Mellitus and accompanying com-
plications can be used to forecast the economic burden of the disease to the clinics.
The mean age indicates delay in diagnosing diabetes and accompanying compli-
cation which has cost implications. This calls for policies that will help in the early
detection in clinical practice and effective management protocols by Cocoa clinics.
Keywords: Diabetes, financial cost, Cocoa clinics, complication, Cost-of-illness,
Ghana.
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OBJECTIVES: To estimate annual treatment costs attributable to obesity (TC-ATO)
in diabetes patients in the US. METHODS: The study used Medical Expenditure
Panel Survey data from 2001-2008, a nationally representative sample of US non-
institutionalized population. Diabetic patients(18 years old) were identified using
ICD-9-CM code 250, clinical classification codes 049 and 050, or physician reported
diagnosis. Patients were classified as normal (body mass index(BMI)18.5-25 kg/
m2), overweight (BMI 25-30 kg/m2), or obese (BMI30 kg/m2). Patients with preg-
nancy, malignancy, kidney dialysis, immunodeficiency, or low BMI18.5 kg/m2
were excluded. Treatment costs included all costs for treating diabetic patients,
excluding dental health and injury costs. Adjusted costs were calculated using
generalized linear model(GLM) with log link function and gamma distribution. TC-
ATOs were estimated using recycled prediction and quantile regression method.
The recycled prediction method predicted costs for obese patients by calculating
costs using estimated coefficients from normal patients using GLM after adjusting
for the study variables. TC-ATO was the differences between actual costs and
predicted costs in the obese patients. In quantile regression, TC-ATO for each
quantile was estimated as the coefficient of the obese patients. All costs were
converted to 2010 US dollars using price indices. RESULTS: The average treatment
costs were $9,196 (95%CI:$8,213-$10,178) and $9,614 (95%CI:$9,124-$10,104) for nor-
mal and obese patients, respectively. The treatment costs in obese patients were
12% higher than those in normal patients after adjusting for other study vari-
ables(p0.029). Overall, the average TC-ATO in diabetic patients was predicted to
be $527(95%CI:$49-$1,005). TC-ATO calculated by quantile regression were
$154(95%CI:$68-240), $253(95%CI:$165-$342), $395(95%CI:$246-$545), $705(95%CI:
$395-$1,015) and $920($443-$1,397) for 10th, 25th, 50th, 75th, and 90th percentile,
respectively. CONCLUSIONS: Obese patients with diabetes have significantly
higher treatment costs compared to normal diabetic patients. The increased eco-
nomic burden attributable to obesity represents potentially avoidable costs, which
justifies allocating additional resources to therapeutic interventions aimed at re-
ducing weight.
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